Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed the day trading at $71.52 up 3.56% from the previous closing price of $69.06. In other words, the price has increased by $3.56 from its previous closing price. On the day, 1.17 million shares were traded. MIRM stock price reached its highest trading level at $72.08 during the session, while it also had its lowest trading level at $68.79.
Ratios:
For a better understanding of MIRM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 416.36. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
On April 17, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $48.Stifel initiated its Buy rating on April 17, 2024, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Peetz Christopher sold 40,000 shares for $62.00 per share. The transaction valued at 2,480,000 led to the insider holds 138,641 shares of the business.
CHRISTOPHER PEETZ bought 40,000 shares of MIRM for $2,480,000 on Aug 11 ’25. On Aug 07 ’25, another insider, Howe Jolanda, who serves as the SVP, GLOBAL CONTROLLER of the company, sold 10,000 shares for $58.00 each. As a result, the insider received 580,000 and left with 2,426 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3592993024 and an Enterprise Value of 3607342592. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.37 while its Price-to-Book (P/B) ratio in mrq is 14.03. Its current Enterprise Value per Revenue stands at 8.406 whereas that against EBITDA is -109.782.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.89, which has changed by 0.6601671 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $69.27, while it has fallen to a 52-week low of $36.86. The 50-Day Moving Average of the stock is 30.56%, while the 200-Day Moving Average is calculated to be 51.46%.
Shares Statistics:
Over the past 3-months, MIRM traded about 518.91K shares per day on average, while over the past 10 days, MIRM traded about 982530 shares per day. A total of 50.06M shares are outstanding, with a floating share count of 40.53M. Insiders hold about 19.31% of the company’s shares, while institutions hold 94.46% stake in the company. Shares short for MIRM as of 1753920000 were 6634186 with a Short Ratio of 12.78, compared to 1751241600 on 6512657. Therefore, it implies a Short% of Shares Outstanding of 6634186 and a Short% of Float of 13.25.
Earnings Estimates
The current assessment of Mirum Pharmaceuticals Inc (MIRM) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.14, with high estimates of $0.07 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.34 and -$1.0 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is $0.06, with 9.0 analysts recommending between $1.28 and -$0.74.
Revenue Estimates
8 analysts predict $129.21M in revenue for the current quarter. It ranges from a high estimate of $134.16M to a low estimate of $122.3M. As of the current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $90.38MFor the next quarter, 8 analysts are estimating revenue of $135.87M. There is a high estimate of $140.79M for the next quarter, whereas the lowest estimate is $129.7M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $513.83M, while the lowest revenue estimate was $491.6M, resulting in an average revenue estimate of $504.24M. In the same quarter a year ago, actual revenue was $336.89MBased on 10 analysts’ estimates, the company’s revenue will be $600.04M in the next fiscal year. The high estimate is $650.83M and the low estimate is $558.04M.
